The combination of enzalutamide and anti–PD-1 treatment significantly increased TIDC1 cells and significantly decreased both tumor-infiltrating dendritic cells type 2 (TIDC2; CD45+CD11c+F4/80–CD11b–CD103+) cells and myeloid-derived suppressor cells (MDSCs; CD45+CMH2+CD11b+Ly6CHighLy6G–GR1Low) cells compared with either monotherapy or controls (Fig. 4G–I). Here, PDCD1 is linked to neoplasm.